Arcellx CEO Rami Elghandour's Equity Disposition Following Gilead Sciences Acquisition

This Form 4 filing reports the disposition of all equity holdings by Rami Elghandour, President, CEO and Chairman of Arcellx, Inc., following the company's acquisition by Gilead Sciences. The transactions occurred on April 28, 2026, pursuant to the merger agreement dated February 22, 2026. Elghandour disposed of 692,551 shares of common stock directly and indirectly through various trusts and a family foundation. Additionally, he disposed of 2,525,000 stock options and 1,025,000 restricted stock units/performance-based restricted stock units. All equity interests were converted into cash payments of $115 per share plus contingent value rights as part of the merger consideration. The filing represents the complete liquidation of the executive's equity position in Arcellx following the acquisition.